Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy - A European Perspective

Thrombosis Research

Volumn 129, Issue 4, 2012, Pages 426-433

  Alatri, Adriano ^a   Armstrong, Anna Elina ^b   Greinacher, Andreas ^c   Koster, Andreas ^d   Kozek Langenecker, Sibylle A ^e   Lancé, Marcus D ^f   Link, Andreas ^g   Nielsen, Jørn D ^h   Sandset, Per M ⁱ   Spanjersberg, Alexander J ^j   Spannagl, Michael ^k  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e Evangelisches Krankenhaus Vienna   (Austria)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g SAARLAND UNIVERSITY   (Germany)

^h Rigshospitalet   (Denmark)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j ISALA HOSPITAL   (Netherlands)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

more..

Author keywords

anticoagulation; argatroban; heparin induced thrombocytopenia; intensive care unit patients

Indexed keywords

ARGATROBAN; HEPARIN; PHENPROCOUMON; WARFARIN;

APACHE; CONSENSUS DEVELOPMENT; DISEASE SEVERITY; DRUG MONITORING; GENDER; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INTENSIVE CARE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

EID: 84858337064     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.11.041     Document Type: Review

References (86)

1. A. Greinacher, B. Pötzsch, J. Amiral, V. Dummel, A. Eichner, and C. Müller-Eckhardt Heparin-induced thrombocytopenia: isolation of the antibody and characterization of a multi-molecular PF4-heparin complex as the major antigen Thromb Haemost 71 1994 247 251
2. J.G. Kelton, J.W. Smith, T.E. Warkentin, C.P. Hayward, G.A. Denomme, and P. Horsewood Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4 Blood 83 1994 3232 3239
3. G.P. Visentin, S.E. Ford, J.P. Scott, and R.H. Aster Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells J Clin Invest 93 1994 81 88
4. J.G. Kelton, D. Sheridan, A. Santos, J. Smith, K. Steeves, and C. Smith Heparin-induced thrombocytopenia: laboratory studies Blood 72 3 1988 925 930
5. T.E. Warkentin, C.P.M. Hayward, L.K. Boshkov, A.V. Santos, J.A. Sheppard, and A.P. Bode Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia Blood 84 1994 3691 3699
6. J.G. Kelton The pathophysiology of heparin-induced thrombocytopenia. Biological basis for treatment Chest 127 2005 9S 20S
7. P.M. Newman, and B.H. Chong Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified antiPF4-heparin antibodies to platelets and the resultant platelet activation Blood 96 2000 182 187
8. T.E. Warkentin, M.N. Levine, J. Hirsh, P. Horsewood, R.S. Roberts, and M. Gent Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330 1335
9. T.E. Warkentin Clinical Picture of heparin-induced thrombocytopenia T.E. Warkentin, A. Greinacher, Heparin-induced thrombocytopenia 4th edition 2008 Informa Healthcare USA Inc. New York, London
10. G.M. Arepally, and T.L. Ortel Heparin-induced thrombocytopenia N Engl J Med 355 2006 809 817
11. T.E. Warkentin, A. Greinacher, A. Koster, and A.M. Lincoff Treatment and Prevention of Heparin-Induced Thrombocytopenia American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 340 380
12. J.R. Bartholomew Heparin-induced thrombocytopenia: 2008 update Curr Treat Options Cardiovasc Med 10 2 2008 117 127
13. E. Shantsila, G.Y.H. Lip, and B.H. Chong Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management Chest 135 6 2009 1651 1664
14. A.K. Verma, M. Levine, S.J. Shalansky, C.J. Carter, and J.G. Kelton Frequency of heparin-induced thrombocytopenia in critical care patients Pharmacotherapy 23 6 2003 745 753
15. S. Uchino, J.A. Kellum, R. Bellomo, G.S. Doig, H. Morimatsu, and S. Morgera Acute renal failure in critically ill patients. A multinational, multicenter study JAMA 294 7 2005 813 818
16. M.H. Ebell, J. Siwek, B.D. Weiss, S.H. Woolfe, J. Susman, and B. Ewigman Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature Am Fam Physician 69 2004 548 556
17. M.J. Hursting, and C.N. Verme-Gibboney Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with Argatroban: a retrospective study J Cardiovasc Pharmacol 52 6 2008 561 566
18. T.E. Warkentin, and A. Greinacher Heparin-induced thrombocytopenia 4th ed 2008 Informa Healthcare USA Inc New York, London
19. A. Greinacher Immunogenic but effective: the HIT-fondaparinux brain puzzler 2011 10.1111/j.1538-7836.2011.04511.x
20. A. Koster, S. Huebler, E. Potapov, O. Meyer, M. Jurmann, and Y. Weng Impact of heparin-induced thrombocytopenia on outcome in patients with ventricular assist device support: singel-institution experience in patients 358 consecutive patients Ann Thorac Surg 83 2007 72 76
21. T.E. Warkentin, J.-A.I. Sheppard, P. Horsewood, P.J. Simpson, J.C. Moore, and J.G. Kelton Impact of patient population art risk for heparin-induced thrombocytopenia Blood 96 2000 1703 1708
22. T.E. Warkentin, J.A. Sheppard, C.S. Sigouin, T. Kohlmann, P. Eichler, and A. Greinacher Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia Blood 108 9 2006 2937 2941
23. R.J. Cipolle, K.A. Rodvold, R. Seifert, R. Clarens, and M. Ramirez-Lassepas Heparin-induced thrombocytopenia: a prospective evaluation of 211 patients Ther Drug Monit 5 1983 205 211
24. P. Prandoni, S. Siragusa, B. Girolami, and F. Fabris BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study Blood 106 2005 3049 3054
25. F.M. Creekmore, G.M. Oderda, R.C. Pendleton, and D.I. Brixner Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism Pharmacotherapy 26 2006 1438 1445
26. A. Greinacher, P. Eichler, T. Lietz, and T.E. Warkentin Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of its lower frequency og heparin-induced thrombocytopenia Blood 106 8 2005 2921 2922
27. C. Pouplard, M.A. May, S. Regina, M. Marchand, J. Fusciardi, and Y. Gruel Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies Br J Haematol 128 2005 837 841
28. N. Martel, J. Lee, and P.S. Wells Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis Blood 106 2005 2710 2715
29. M. Ramirez-Lassepas, R.J. Cipolle, K.A. Rodvold, R.D. Seifert, L. Strand, and L. Taddeini Heparin-induced thrombocytopenia in patients with cerbrovascular ischemic disease Neurology 34 1984 736 740
30. P. Prandoni, A. Falanga, and A. Picciolo Cancer, thrombosis and heparin-induced thrombocytopenia Thromb Res 120 suppl 2 2007 S137 S140
31. G.K. Lo, D. Juhl, T.E. Warkentin, C.S. Sigouin, P. Eichler, and A. Greinacher Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings J Thromb Haemost 4 2006 759 765
32. N. Lubenow, P. Hinz, S. Thomaschewski, T. Lietz, M. Vogler, and A. Ladwig The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia Blood 115 9 2010 1797 1803
33. T.E. Warkentin, B.H. Chong, and A. Greinacher Heparin-induced thrombocytopenia: towards consensus Thromb Haemost 79 1998 1 7
34. F. Fabris, G. Luzatto, P.M. Stefani, B. Girolami, G. Cella, and A. Girolami Heparin-induced thrombocytopenia Haematologica 85 2000 72 81
35. T.E. Warkentin Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Recommendations of the College of American Pathologists Arch Pathol Lab Med 126 2002 1415 1423
36. A. Greinacher, B. Farner, H. Kroll, T. Kohlmann, T.E. Warkentin, and P. Eichler Clinical features of geparin-induced thrombocytopenia including risk factors for thrombosis Thromb Haemost 94 2005 132 135
37. T.E. Warkentin Think of HIT Hematology 2006 408 414
38. A. Greinacher, and T.E. Warkentin Risk of heparin-induced thrombocytopenia in patients receiving thromboprophylaxis Expert Rev Hematol 1 1 2008 75 85
39. T.E. Warkentin, R.S. Roberts, J. Hirsh, and J.G. Kelton Heparin-induced skin lesions and other unusual sequelae of the heparin-induced syndrome: a nested cohort study Chest 127 2005 1857 1861
40. M. Schindewolf, S. Schwaner, M. Wolter, H. Kroll, A. Recke, and R. Kaufmann Incidence and cause of heparin-induced skin lesions CMAJ 181 8 2009 477 481
41. T.E. Warkentin, and A. Greinacher Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes Expert Opin Drug Saf 8 2 2009 129 144
42. T.E. Warkentin, and J.G. Kelton Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT Blood 92 suppl 1 1998 182a
43. T.E. Warkentin, and J.G. Kelton Temporal aspects of heparin-induced thrombocytopenia N Engl J Med 344 2001 1286 1292
44. T.E. Warkentin, and D. Cook Heparin, Low Molecular Weight Heparin, and Heparin-Induced Thrombocytopenia in the ICU Crit Care Clin 21 3 2005 513 529
45. G.K. Lo, C.S. Sigouin, and T.E. Warkentin What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82 2007 1037 1043
46. R.L. Levine, G.W. Hergenroeder, J.L. Francis, C.C. Miller, and M.J. Hursting Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study J Thromb Thrombolysis 30 2 2009 142 148
47. C. Pouplard, J. Amiral, J.Y. Borg, S. Laporte-Simitsidis, B. Delahousse, and Y. Gruel Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4-enzyme-linked immunoabsorbent assay for diagnosis of hepartin-induced thrombocytopenia Am J Clin Pathol 111 1999 700 706
48. T. Bakchol, A. Giptner, A. Najaoui, G. Bein, S. Santoso, and U.J.H. Sachs Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia J Thromb Haemost 7 2009 1260 1265
49. A. Greinacher Heparin-induced thrombocytopenia J Thromb Haemost 7 Suppl 1 2009 9 12
50. D. Sheridan, C. Carter, and J.G. Kelton A diagnostic test for heparin-induced thrombocytopenia Blood 67 1986 27 30
51. M. Fouassier, E. Bourgerette, F. Libert, C. Pouplard, and A. Marques-Verdier Determination of serotonin release from platelets by HPLC and ELISA in the diagnosis of heparin-induced thrombocytopenia: comparison with reference method by [14C]-serotonin J Thromb Haemost 4 2006 1136 1139
52. P. Eichler, U. Budde, S. Haas, H. Kroll, R.M. Loreth, and O. Meyer First workshop for detection of heparin-induced antibodies: validation of the heparin-induced platelet activation test (HIPA) in comparison with PF4/heparin ELISA Thromb Haemost 81 1999 625 629
53. A. Greinacher, J. Amiral, V. Dummel, A. Vissac, B. Kiefel, and C. Mueller-Eckhardt Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunoabsorbent assay Transfusion 34 1994 381 385
54. J.M. Walenga, W.P. Jeske, A.R. Fasanella, J.J. Wood, S. Ahmad, and M. Bakhos Laboratory diagnosis of heparin-induced thrombocytopenia Clin Appl Thrombosis/Hemostasis 5 suppl 1 1999 S21 S27
55. O. Izawa, M. Katsuki, T. Komatsu, and S. Iida Pharmacokinetic studies of argidipine (MD-805) in human - concentrations of argidipine and its metabolites in plasma, urine, feces during and after drip intravenous infusion Jpn J Pharmacol Ther 14 suppl 5 1986 251 263
56. S.K. Swan, and M.J. Hursting The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction Pharmacotherapy 20 3 2000 318 329
57. H. Nagasawa, K. Fukutake, and M. Hada Phase one study of synthetic antithrombin agent (MD-805) single and multiple admnistration studies Jpn J Pharmacol Ther 12 1981 359 375
58. J.M. Walenga, S. Ahmad, D. Hoppensteadt, O. Iqbal, M.J. Hursting, and B.E. Lewis Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia Thromb Res 105 2002 401 405
59. C.N. Verme-Gibboney, and M.J. Hursting Argatroban dosing in patients with heparin-induced thrombocytopenia Ann Pharmacother 37 7 2003 970 975
60. W.D. Hoffman, Y. Czyz, D.A. McCollum, and M.J. Hursting Reduced argatroban doses after coronary artery bypass graft surgery Ann Pharmacother 42 3 2008 309 316
61. S. Okamoto, and A. Hijikata Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereostructure of its hydrophobic carboxamide portion Biochem Biophys Res Commun 101 2 1981 440 446
62. L.R. Bush Argatroban, a selective, potent thrombin inihibitor Cardiovasc Drug Rev 9 3 1991 247 263
63. B.E. Lewis, D.E. Wallis, S.D. Berkowitz, W.H. Matthai, J. Fareed, and J.M. Walenga Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia Circulation 103 2001 1838 1843
64. B.E. Lewis, D.E. Wallis, F. Leya, M.J. Hursting, and J.G. Kelton Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia Arch Intern Med 163 2003 1849 1856
65. S.K. Swan, J.V. St. Peter, L.J. Lambrecht, and M.J. Hursting Comparison of anticoagulant effects and safety of argatroban in healthy subjects Pharmacotherapy 20 7 2000 756 770
66. U. Lange, G. Nowak, and E. Bucha Ecarin chromogenic assay - a new method for quantitative determination of direct thrombin inhibitors Pathophysiol Haemost Thromb 33 2003/04 184 191
67. A.J. Ansara, S. Arif, and R.D. Warhurst Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia Ann Pharmacother 43 1 2009 9 18
68. M. Beiderlinden, T.A. Treschan, K. Görlinger, and J. Peters Argatroban anticoagulation in critically ill patients Ann Pharmacother 41 5 2007 749 754
69. S.P. Keegan, E.M. Gallagher, N.E. Ernst, E.J. Young, and E.W. Mueller Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia Ann Pharmacother 43 1 2009 19 27
70. A. Link, M. Girndt, S. Selejan, A. Mathes, M. Böhm, and H. Rensing Argatroban for anticoagulation in continuous renal replacement therapy Crit Care Med 37 1 2009 105 110
71. A. Link, S. Selejan, A. Mathes, M. Böhm, and H. Rensing Argatroban for anticoagulation in continuous renal replacement therapy (the authors reply) Crit Care Med 37 6 2009 2139 2140
72. B.V. Reddy, E.J. Grossman, S.A. Trevino, M.J. Hursting, and P.T. Murray Argatroban anticoagulation in patients with heparin-induced thrmbocytopenia requiring renal replacement therapy Ann Pharmacother 39 10 2005 1601 1605
73. P.T. Murray, B.V. Reddy, E.J. Grossman, M.S. Hammes, S. Trevino, and J. Ferrell A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease Kidney Int 66 2004 2446 2453
74. N. Lubenow, S. Selleng, H.-G. Wollert, P. Eichler, B. Müllejans, and A. Greinacher Heparin-induced thrombocytopenia and cardiopulmonary bypass: perioperative argatroban use Ann Thorac Surg 75 2003 577 579
75. S.E. Hallman, L. Hebbar, J. Robison, and W.E. Uber The use of argatroban for carotid endarterectomy in heparin-induced thrombocytopenia Anesth Analg 100 2005 946 948
76. J.L. Liedel, N. Panicker, and M.D. Kahana Argatroban for anticoagulation in children with heparin-induced platelet antibodies.[abstr] Crit Care Med 31 2003 A132
77. M.J. Hursting, J. Dubb, and C.N. Verme-Gibboney Argatroban anticoagulation in pediatric patients J Pediatr Hematol Oncol 28 2006 4 10
78. G. Young, L.K. Boshkov, J.E. Sullivan, L.J. Raffini, D.S. Cox, and D.A. Boyle Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokintec study Pediatr Blood Cancer 56 2011 1103 1109
79. T. Kawada, H. Kitagawa, M. Hoson, Y. Okada, and J. Shiomura Clinical application of argatroban as an alternative anticoagulant for extracorporeal circulation Hematol Oncol Clin North Am 14 2000 445 457
80. Y. Okada, T. Kawada, and M. Hoson Use of an antithrombotic agent, argatroban, in two patients with ECMO after pediatric open heart surgery Jpn J Thromb Haemost 11 2000 201 204
81. L.K. Boshkov, L. Ibsen, A. Kirby, R. Ungerleider, and I. Shen Heparin-induced thrombocytopenia (HIT) in neonates and very young children undergoing congenital cardiac surgery: a likely under-recognized complication with significant morbidity and mortality: report of 4 sequential cases J Thromb Haemost suppl 1 2003 1494
82. L.K. Boshkov, L. Ibsen, A. Kirby, R. Ungerleider, and I. Shen Report of argatroban infusions for heparin-induced thrombocytopenia (HIT) diagnosed by functional assay in 2 congenital cardiac surgery patients, a neonate and a 5 month old J Thromb Haemost suppl 1 2003 1495
83. L.K. Scott, L.R. Grier, and S.A. Conrad Heparin-induced thrombocytopenia in a pediatric patient receiving extracorporal membrane oxygenation managed with argatroban Pediatr Crit Care Med 7 2006 473 475
84. K.E. Potter, A. Raj, and J.E. Sullivan Argatroban for anticoagulation in pediatric patients with heparin-induced thrombocytopenia requiring extracorporal life support J Pediatr Hematol Oncol 29 2007 265 268
85. M.J. Hursting, B.E. Lewis, and D.E. Macfarlane Transitioning from aragtroban to warfarin therapy in patients with heparin-induced thrombocytopenia Clin Appl Thrombosis/Hemostasis 11 3 2005 279 287
86. S. Harder, J. Graff, U. Klinkhardt, N. von Hentig, J.M. Walenga, and H. Watanabe Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time and ecarin clotting time Thromb Haemost 91 2004 1137 1145